Use Clause 92 of the Indian Patent Act, break Remdesivir monopoly, issue Compulsory License

India is one of the largest generic drug manufacturers in the world and there should be no reason why Remdesivir and other COVID-19 drugs cannot be made available rapidly and at affordable prices to India and the world.

Modi Government slept over Chinese encroachment in Ladakh since 2015

As the face-off between India and China continues in the newly formed Union Territory of Ladakh, Modi Government’s inability to deal with China comes...

Chinese firms barred from Indian road projects, investing in MSME

We must critically examine the ongoing trade, import of domestic and industrial products and the method of tendering, bidding and execution of projects in the country.

My Doctor wife shows how to beat COVID 19 like a boss

Covid19 was declared a pandemic in the first quarter of 2020. Everyone’s lives changed. We, the doctors who were looked down upon by the...

Corona, Infrared thermometers and the call to ban made in China products

The first time, the infrared thermometer, in the shape of a pistol was pointed at my head when I visited a bank with a...